奎硫平合并丙戊酸镁缓释片治疗精神分裂症兴奋激越研究

Study of quetiapine combined with magnesium valproate release tablets in treatment of schizophrenia with symptoms of elation and agitation

目的:比较奎硫平合并丙戊酸镁缓释片与氟哌啶醇治疗精神分裂症患者伴有兴奋、激越症状的疗效及不良反应。方法:对精神分裂症住院患者采用随机对照、开放性研究治疗2周。以阳性与阴性症状量表(PANSS)及临床疗效总评量表(CGI)评估疗效,以治疗中出现的症状量表(TESS)评估不良反应。结果:合用组与对照组的总体疗效相当,兴奋、激越症状的控制前者优于后者(P<0.05);不良反应方面,氟哌啶醇引起的锥体外系不良反应较奎硫平合并丙戊酸镁缓释片高。结论:奎硫平合并丙戊酸镁缓释片对精神分裂症兴奋、激越症状的疗效优于氟哌啶醇,且不良反应较小。

Objective： To compare the efficacy and tolerability between quetiapine combined with magnesium valproate release tablets and haloperidol in the treatment of schizophrenia with symptoms of elation and agitation. Method： A random, controlled and opening study was adopted in the inpatients with schizophrenia. The patients were divided into quetiapine combined with magnesium valproate release tablets （combined group） or haloperidol only （control group） for two weeks. The positive and negative symptoms scale （PANSS）, clinical global impression scale （CGI） and treatment emergent symptom scale （TESS）were used to assess the efficacy and safety. Results： There was no significant difference in the overall efficiency between two groups, but the combined group had better effect in controlling the symptoms of elation and agitation （ P 〈 0.05）. The side effects of extrapyramidal symptoms were more sever in control group than in combined group. Conclusion： Quetiapine combined with magnesium valproate release tablets has good effect on schizophrenia with symptoms of elation and agitation, with few side effects.